Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic.
BIOCEV (Biotechnology and Biomedicine Center in Vestec), First Faculty of Medicine, Charles University, Prumyslova 595, CZ-252 50 Vestec, Czech Republic.
Trends Cancer. 2023 Apr;9(4):293-308. doi: 10.1016/j.trecan.2023.01.001. Epub 2023 Feb 15.
Most cancer-related deaths among patients with solid tumors are caused by metastases. Migrastatic strategies represent a unique therapeutic approach to prevent all forms of cancer cell migration and invasion. Because the migration machinery has been shown to promote metastatic dissemination, successful migrastatic therapy may reduce the need for high-dose cytotoxic therapies that are currently used to prevent the risk of metastatic dissemination. In this review we focus on anti-invasive and antimetastatic strategies that hold promise for the treatment of solid tumors. The best targets for migrastatic therapy would be those that are required by all forms of motility, such as ATP availability, mitochondrial metabolism, and cytoskeletal dynamics and cell contractility.
大多数实体瘤患者的癌症相关死亡是由转移引起的。迁移抑制策略代表了一种独特的治疗方法,可防止所有形式的癌细胞迁移和侵袭。因为已经表明迁移机制可促进转移扩散,因此成功的迁移抑制治疗可能会减少目前用于预防转移扩散风险的高剂量细胞毒性治疗的需求。在这篇综述中,我们重点介绍了具有治疗实体瘤潜力的抗侵袭和抗转移策略。迁移抑制治疗的最佳靶点将是所有形式的运动所必需的靶点,例如 ATP 可用性、线粒体代谢以及细胞骨架动力学和细胞收缩性。